𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements

✍ Scribed by Angel F. Remacha; Beatriz Arrizabalaga; Consuelo Del Cañizo; Guillermo Sanz; Ana Villegas

Publisher
Springer
Year
2009
Tongue
English
Weight
147 KB
Volume
89
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Red blood cell transfusions and iron ove
Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes
✍ Elias Jabbour; Hagop M. Kantarjian; Charles Koller; Ali Taher 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views

## Abstract ## BACKGROUND Approximately 15,000 new cases of myelodysplastic syndromes (MDS) are expected in the United States each year. ## METHODS The mainstay for the management of myelodysplastic syndromes (MDS) is supportive therapy with red blood cell (RBC) transfusions to improve the patie

Improved survival in red blood cell tran
Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy
✍ Heather A. Leitch; Jocelyn M. Chase; Trisha A. Goodman; Hatoon Ezzat; Meaghan D. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

## Abstract Many patients with primary myelofibrosis (PMF) become red blood cell (RBC) transfusion dependent (TD), risking iron overload (IOL). Iron chelation therapy (ICT) may decrease the risk of haemosiderosis associated organ dysfunction, though its benefit in PMF is undefined. To assess the ef